TickerFacts.

Skinvisible, Inc. (SKVI): Capital Expenditures

Annual figures by period end, from SEC filings.

$4.1K
Year ended 2025-12-31
$9.2K2024-12-31: $9.2K2025-12-31: $4.1K$4.1K
2024-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$4.1K-55.7%2026-03-31, From 2025-01-01
2024-12-31$9.2Kn/a2026-03-31, From 2024-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Skinvisible, Inc. (SKVI)2025-12-31$4.1K-55.7%
Bioadaptives, Inc. (BDPT)2025-12-31$18.0Kn/a
PRF Technologies Ltd. (PRFX)2025-12-31$2.0K-84.6%
Talphera, Inc. (TLPH)2024-12-31$0-100.0%
Lyell Immunopharma, Inc. (LYEL)2025-12-31$780.0K+68.1%
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31$500.0Kn/a
Altimmune, Inc. (ALT)2025-12-31$11.0Kn/a
Genelux Corp (GNLX)2025-12-31$1.10M+188.2%
HCW Biologics Inc. (HCWB)2025-12-31$0-100.0%

Compare SKVI, BDPT, PRFX, TLPH side by side · Screen every company in Pharmaceutical Preparations ↗